Soleno Therapeutics (SLNO) Equity Average (2016 - 2019)
Historic Equity Average for Soleno Therapeutics (SLNO) over the last 6 years, with Q3 2019 value amounting to $14.4 million.
- Soleno Therapeutics' Equity Average fell 437.39% to $14.4 million in Q3 2019 from the same period last year, while for Sep 2019 it was $14.4 million, marking a year-over-year decrease of 437.39%. This contributed to the annual value of $28.6 million for FY2018, which is 8917.63% up from last year.
- Soleno Therapeutics' Equity Average amounted to $14.4 million in Q3 2019, which was down 437.39% from $18.7 million recorded in Q2 2019.
- In the past 5 years, Soleno Therapeutics' Equity Average ranged from a high of $28.4 million in Q2 2017 and a low of -$11.2 million during Q1 2015
- Moreover, its 5-year median value for Equity Average was $15.0 million (2018), whereas its average is $12.1 million.
- In the last 5 years, Soleno Therapeutics' Equity Average skyrocketed by 57304.59% in 2017 and then plummeted by 3979.32% in 2018.
- Soleno Therapeutics' Equity Average (Quarter) stood at $966408.0 in 2015, then skyrocketed by 373.26% to $4.6 million in 2016, then soared by 446.91% to $25.0 million in 2017, then dropped by 10.81% to $22.3 million in 2018, then plummeted by 35.61% to $14.4 million in 2019.
- Its last three reported values are $14.4 million in Q3 2019, $18.7 million for Q2 2019, and $27.0 million during Q1 2019.